Efficacy and safety of a feline immunodeficiency virus vaccine

  title={Efficacy and safety of a feline immunodeficiency virus vaccine},
  author={Chengjin M. Huang and Douglas Conlee and Jennifer Loop and D. R. Champ and Michael A. Gill and H J Chu},
  journal={Animal Health Research Reviews},
  pages={295 - 300}
Abstract Fel-O-Vax FIV is an inactivated virus vaccine designed as an aid in the prevention of infection of cats, 8 weeks or older, by feline immunodeficiency virus (FIV). It contains two genetically distinct FIV strains. The efficacy of this vaccine was demonstrated in a vaccination–challenge study designed to meet various regulatory requirements for registering the vaccine. Eight-week-old kittens were vaccinated with an immunogenicity vaccine which contained minimal release levels of FIV… 
Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine
Future efforts in developing the next generation FIV vaccine and the first effective HIV-1 vaccine should consider incorporating highly conserved protective T-cell epitopes together with the Conserved protective B- cell epitopes, but without inducing adverse factors that eliminate efficacy.
Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge
Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Findings from these studies are being used to define the prophylactic epitopes needed for an HIV-1 vaccine for humans.
Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats.
A practical strategy for the diagnosis of FIV infection would be to use existing commercial FIV antibody assays as screening tests, which are highly reliable predictors for lack of infection.
Sequence variation of the feline immunodeficiency virus genome and its clinical relevance
It is important that the key determinants of immunity induced by this vaccine are discovered; such data would compliment vaccine field efficacy studies and provide the basis to make informed recommendations on its use.
Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax® FIV)
The antibody response to inactivated Fel-O-Vax® FIV whole-virus vaccine is outlined, and how best to diagnose FIV infection in jurisdictions where FIV vaccination is practiced is demonstrated.
2008 American Association of Feline Practitioners' feline retrovirus management guidelines
Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.
The most effective way to enhance the quality of life and life expectancy of FIV-infected cats is to optimise basic husbandry and to treat any concurrent conditions early in the disease course.


Experimental vaccine protection against feline immunodeficiency virus.
The results indicate that vaccine prophylaxis against natural FIV infection should be achievable and enhance optimism of the prospect of developing an effective AIDS vaccine for humans.
FIV vaccine development and its importance to veterinary and human medicine: a review
Phylogenetic analysis of feline immunodeficiency virus in Central Europe: a prerequisite for vaccination and molecular diagnostics.
A phylogenetic analysis of 30 FIV strains derived from Central Europe points to the existence of extensive virus variation with the presence of at least two highly divergent subtypes of FIV in Austria and Germany.
Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.
It is concluded that in many respects FIV is an ideal model for AIDS studies because its susceptibility to antiviral agents is similar to that of HIV, thus providing a valuable system for in vivo preclinical evaluation of therapies.
Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission.
The epidemiologic features of feline immunodeficiency virus (FIV) infection were evaluated in 2,765 cats from the United States and Canada and there was a pronounced linkage between FIV and feline syncytium-forming virus (FeSFV) infections.
Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.
A highly T-lymphotropic virus was isolated from cats in a cattery in which all the animals were seronegative for feline leukemia virus, and appears to be antigenically distinct from human immunodeficiency virus.
Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom
It was concluded that both viruses were significant causes of disease, and that the cats most likely to be infected with FIV were older, free-roaming male cats and for FeLV, younger, free -roaming cats.
Comparison of six in-house tests for the rapid diagnosis of feline immunodeficiency and feline leukaemia virus infections
Six rapid tests for the diagnosis of feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLv) infections which have recently been introduced in Europe for use in small animal practice
Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus and feline coronavirus in stray cats sent to an RSPCA hospital
The prevalence of FIV antibodies was significantly higher in entire males and neutered males than in females, in cats over two years old compared with younger cats, and in cats suffering disease of non-traumatic origin rather than in healthy cats or cats suffering only from trauma.
At-risk individuals in Feline Immunodeficiency Virus epidemiology: evidence from a multivariate approach in a natural population of domestic cats (Felis catus)
A study of the cats group size and of the spatial distribution of infected individuals indicates the absence of infection clusters in males, and suggests the importance of roaming in the spreading of FIV.